Advisory Committee on Epinephrine Nasal Spray

Federal Register notice: FDA has announced a 5/11 Pulmonary-Allergy Drugs Advisory Committee meeting to discuss an ARS Pharmaceuticals NDA for epinephrine nasal spray, indicated for emergency treatment of allergic reactions (Type I) including anaphylaxis in adults and children. To view the notice, click here.

Read more